Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
We understand that every individuals experience is unique, and we are here to address your needs, celebrate your successes, and overcome any challenges together
STEP 1 Trial: Adults with obesity lost an average of 14.9% of their body weight at 68 weeks with Semaglutide compared to 2.4% with placebo
These syringes come in 0.3ml (30 unit), 0.5ml (50 unit), and 1.0ml (100 unit) sizes
Stettler C, Allemann S, Jni P, et al
Consider supplementing with protein powder if whole-food targets feel unattainable due to nausea or appetite suppressiona single scoop of isolate delivers 2025 grams of protein in just a few ounces of liquid, making it an efficient protein delivery tool for semaglutide users